Fundraising Fox

Cellibre

San Diego, US · Founded 2017 · Delaware corporation · 5 known investors

cellibre.com ↗
Biotechin /cellibre@Cellibre1

Founders & leadership

SZScott Zingheim
Scott ZingheimExecutive
SK
Spiros KambourakisExecutive
BC
Benjamin ChiarelliExecutive
NC
Nicky CaiazzaNamed on SEC filing

Investors · 5

Beresford VenturesOrlando
Dellin InvestmentsPhiladelphia
Delta Emerald Ventures
JourneyOne VenturesBouldervia Helene Servillon · inferred
Merida Capital HoldingsNew York

Competitors · 2

by search overlap
Cellino Bio8 shared keywordsCellineobio develops cell engineering and bioprocess technology platforms. The company serves biotech and pharmaceutical research and manufacturing customers.
CellFE5 shared keywordsCellFE develops a microfluidic-based gene editing technology and a benchtop device for research and process development of cell therapies. Its products serve cell therapy researchers and developers, aiming to enable non-viral genome editing that maintains cell viability and scales from discovery to commercial manufacturing.

Companies competing with Cellibre for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements

$20.8M disclosed across 3 rounds · 2019–2024

▶$6.7MraisedOct 2024 · 31 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nicky CaiazzaExecutive Officer, Director
  • Scott ZingheimExecutive Officer, Director
  • Spiros KambourakisExecutive Officer, Director
  • Benjamin ChiarelliExecutive Officer, Director
Offering amount
$23.2M
Amount sold
$6.7M
Minimum investment
$521
First sale
Sep 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.9MraisedSep 2021 · 35 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin ChiarelliExecutive Officer, Director
  • Scott ZingheimExecutive Officer, Director
  • Nicky CaiazzaExecutive Officer, Director
  • Spiros KambourakisExecutive Officer, Director
Offering amount
$15M
Amount sold
$9.9M
Minimum investment
$5K
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.2MraisedJul 2019 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Benjamin ChiarelliExecutive Officer
Offering amount
$5M
Amount sold
$4.2M
Sales commissions
$72K
Placement agents
Paradigm Capital U.S., Inc.
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.